{
  "url": "https://finance.yahoo.com/news/non-small-cell-lung-cancer-111600375.html",
  "authorsByline": "Research and Markets",
  "articleId": "2a0d6434547249c99d7ac6e3d91e536f",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
  "country": "us",
  "language": "en",
  "pubDate": "2025-09-02T11:16:00+00:00",
  "addDate": "2025-09-02T11:28:53.321073+00:00",
  "refreshDate": "2025-09-02T11:28:53.321078+00:00",
  "score": 1.0,
  "title": "Non-Small Cell Lung Cancer (NSCLC) Market Growth Trends and Business Opportunities 2025-2035 by Region",
  "description": "NSCLC therapies have significantly improved survival rates by targeting specific genetic mutations like EGFR, ALK, and ROS1. Challenges remain, including high treatment costs and drug resistance.Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The \"Non-Small Cell Lung Cancer Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035\" report has been added to ResearchAndMarkets's offering.The global NSCLC treatment market is experiencing rapid growth, dr",
  "content": "NSCLC therapies have significantly improved survival rates by targeting specific genetic mutations like EGFR, ALK, and ROS1. Challenges remain, including high treatment costs and drug resistance. Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The \"Non-Small Cell Lung Cancer Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035\" report has been added to ResearchAndMarkets.com's offering.\n\n\n\nThe global NSCLC treatment market is experiencing rapid growth, driven by advancements in immunotherapies, targeted therapies, and combination treatments. The introduction of immune checkpoint inhibitors, such as pembrolizumab and nivolumab, has revolutionized the treatment landscape, offering significant improvements in survival rates for patients with advanced NSCLC. These therapies work by stimulating the body's immune system to target and destroy cancer cells. Additionally, targeted therapies that focus on specific genetic mutations, including EGFR inhibitors, ALK inhibitors, and ROS1 inhibitors, are improving outcomes for patients with specific molecular alterations. These therapies are often more effective than traditional chemotherapy and tend to have fewer side effects, offering more personalized treatment options for patients.\n\n\n\nThe NSCLC market is also witnessing significant advancements in combination therapies, which combine different classes of drugs, such as immune checkpoint inhibitors with chemotherapy or targeted therapies, to enhance efficacy and overcome resistance mechanisms. Ongoing clinical trials are exploring the potential of combining immunotherapy with other novel treatments, such as targeted agents, to achieve better results. Furthermore, the development of novel immunotherapies, including CAR-T cell therapies and cancer vaccines, is expected to further expand treatment options and improve patient outcomes.\n\n\n\nDespite these advancements, the NSCLC market faces several challenges. One of the major barriers is the high cost of immunotherapies and targeted therapies, which can be prohibitively expensive, particularly in low- and middle-income countries. The cost of treatment often places a heavy financial burden on patients and healthcare systems. Additionally, not all patients respond to immunotherapies or targeted therapies, and the development of resistance remains a significant hurdle. Limited awareness of NSCLC, particularly in regions with less access to healthcare, contributes to late-stage diagnosis and delays in treatment initiation. Furthermore, the complexity of personalized treatment regimens, which require molecular testing and continuous monitoring, adds to the challenges of managing NSCLC effectively.\n\n\n\nKey players in the NSCLC treatment market include major pharmaceutical companies such as Merck & Co., Bristol Myers Squibb, F. Hoffmann-La Roche Ltd., and AstraZeneca. These companies are investing heavily in research and development to improve existing therapies, develop new targeted therapies, and explore novel immunotherapy options. Strategic partnerships with research institutions, healthcare providers, and patient advocacy groups are accelerating efforts to expand access to innovative treatments and improve early detection methods. Furthermore, collaborations between biotech firms and pharmaceutical giants are advancing the development of new therapies and diagnostic solutions aimed at improving survival rates and the overall quality of life for NSCLC patients.\n\n\n\nThe global non-small cell lung cancer (NSCLC) treatment market is experiencing significant growth, driven by advancements in immunotherapies, targeted therapies, and a rising global incidence of lung cancer. Innovations in immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have revolutionized the treatment landscape by offering improved survival rates, particularly in advanced-stage patients. Additionally, the development of targeted therapies targeting specific genetic mutations, such as EGFR, ALK, and ROS1 inhibitors, is transforming NSCLC treatment by providing more effective, personalized, and less toxic alternatives to traditional chemotherapy\n\nThe increasing availability of companion diagnostic tests is enhancing the identification of patients who are eligible for these targeted therapies, further expanding the market. Furthermore, the ongoing research into combination therapies, which combine immune checkpoint inhibitors with chemotherapy or targeted therapies, presents promising opportunities for enhancing efficacy and overcoming treatment resistance. The growing adoption of liquid biopsy techniques is also contributing to early detection and better monitoring of treatment responses, thereby driving demand for advanced therapies in the NSCLC market.\n\n\n\nKey Topics Covered\n\n\n\n1. Global Non-Small Cell Lung Cancer Market: Industry Analysis\n\n1.1 Market Overview and Ecosystem\n\n1.2 Epidemiological Analysis\n\n1.3 Key Market Trends\n\n1.3.1 Impact Analysis\n\n1.4 Regulatory Landscape\n\n1.5 Pipeline Analysis\n\n1.6 Market Dynamics\n\n1.6.1 Overview\n\n1.6.2 Market Drivers\n\n1.6.3 Market Restraints\n\n1.6.4 Market Opportunities\n\n\n\n2. Global Non-Small Cell Lung Cancer Market, by Region, ($Million), 2024-2035\n\n2.1 North America\n\n2.1.1 Market Dynamics\n\n2.1.2 Market Sizing and Forecast\n\n2.1.3 North America Non-Small Cell Lung Cancer Market, by Country ($Million), 2024-2035\n\n2.1.3.1 U.S.\n\n2.1.3.2 Canada\n\n2.2 Europe\n\n2.2.1 Market Dynamics\n\n2.2.2 Market Sizing and Forecast\n\n2.2.3 Europe Non-Small Cell Lung Cancer Market, by Country ($Million), 2024-2035\n\n2.2.3.1 U.K.\n\n2.2.3.2 France\n\n2.2.3.3 Germany\n\n2.2.3.4 Italy\n\n2.2.3.5 Spain\n\n2.2.3.6 Rest-of-Europe\n\n2.3 Asia-Pacific\n\n2.3.1 Market Dynamics\n\n2.3.2 Market Sizing and Forecast\n\n2.3.3 Asia-Pacific Non-Small Cell Lung Cancer Market, by Country ($Million), 2024-2035\n\n2.3.3.1 Japan\n\n2.3.3.2 China\n\n2.3.3.3 India\n\n2.3.3.4 Australia\n\n2.3.3.5 South Korea\n\n2.3.3.6 Rest-of-Asia-Pacific\n\n2.4 Rest-of-the-World\n\n2.4.1 Market Dynamics\n\n2.4.2 Market Sizing and Forecast\n\n\n\n3. Global Non-Small Cell Lung Cancer Market: Competitive Landscape and Company Profiles\n\n3.1 Competitive Landscape\n\n3.1.1 Mergers and Acquisitions\n\n3.1.2 Partnership, Alliances and Business Expansion\n\n3.1.3 New Offerings\n\n3.1.4 Regulatory Activities\n\n3.1.5 Funding Activities\n\n3.2 Company Profiles\n\n3.2.1 AstraZeneca\n\n3.2.1.1 Overview\n\n3.2.1.2 Top Products/Product Portfolio\n\n3.2.1.3 Top Competitors\n\n3.2.1.4 Target Customers/End-Users\n\n3.2.1.5 Key Personnel\n\n3.2.1.6 Analyst View\n\n3.2.2 Bayer AG\n\n3.2.3 Boehringer Ingelheim International GmbH\n\n3.2.4 Bristol-Myers Squibb\n\n3.2.5 Eli Lilly and Company\n\n3.2.6 F. Hoffmann-La Roche Ltd.\n\n3.2.7 GSK plc\n\n3.2.8 Merck & Co. Inc.\n\n3.2.9 Novartis AG\n\n3.2.10 Pfizer Inc.\n\n3.2.11 Sanofi\n\n3.2.12 Teva Pharmaceuticals\n\n3.2.13 Others\n\n\n\nFor more information about this report visit https://www.researchandmarkets.com/r/bihipq About ResearchAndMarkets.com\n\nResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900",
  "medium": "Article",
  "links": [
    "https://www.researchandmarkets.com/reports/6155723/non-small-cell-lung-cancer-market-global?utm_source=GNE&utm_medium=PressRelease&utm_code=gvhppk&utm_campaign=2088272+-+Non-Small+Cell+Lung+Cancer+(NSCLC)+Market+Growth+Trends+and+Business+Opportunities+2025-2035+by+Region&utm_exec=jocamspi"
  ],
  "labels": [
    {
      "name": "Roundup"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "new targeted therapies",
      "weight": 0.086086765
    },
    {
      "name": "targeted therapies",
      "weight": 0.08580665
    },
    {
      "name": "NSCLC treatment",
      "weight": 0.08527043
    },
    {
      "name": "NSCLC therapies",
      "weight": 0.084091306
    },
    {
      "name": "new therapies",
      "weight": 0.0753565
    },
    {
      "name": "international market research reports",
      "weight": 0.07505112
    },
    {
      "name": "Global Non-Small Cell Lung Cancer Market",
      "weight": 0.07393056
    },
    {
      "name": "treatment resistance",
      "weight": 0.07351177
    },
    {
      "name": "combination treatments",
      "weight": 0.07256779
    },
    {
      "name": "treatment options",
      "weight": 0.07222796
    }
  ],
  "topics": [],
  "categories": [
    {
      "name": "Health"
    }
  ],
  "taxonomies": [
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.88330078125
    },
    {
      "name": "/Health/Health Foundations & Medical Research",
      "score": 0.73583984375
    },
    {
      "name": "/News/Health News",
      "score": 0.734375
    },
    {
      "name": "/News/Business News/Other",
      "score": 0.6904296875
    },
    {
      "name": "/Business & Industrial/Advertising & Marketing/Marketing",
      "score": 0.529296875
    },
    {
      "name": "/Health/Medical Literature & Resources/Other",
      "score": 0.51904296875
    },
    {
      "name": "/Health/Health Conditions/Cancer",
      "score": 0.515625
    },
    {
      "name": "/Health/Pharmacy/Drugs & Medications",
      "score": 0.48291015625
    },
    {
      "name": "/Health/Medical Facilities & Services/Medical Procedures/Other",
      "score": 0.3212890625
    }
  ],
  "sentiment": {
    "positive": 0.6319975,
    "negative": 0.06424813,
    "neutral": 0.3037544
  },
  "summary": "The Non-Small Cell Lung Cancer (NSCLC) Market Growth Trends and Business Opportunities 2025-2035 by Region is being published by ResearchAndMarkets. The report highlights the rapid growth of the global NSCLC treatment market driven by advancements in immunotherapies, targeted therapies, and combination treatments. These therapies have significantly improved survival rates by targeting specific genetic mutations like EGFR, ALK, and ROS1. However, challenges remain, including high treatment costs and drug resistance. Major pharmaceutical companies such as Merck & Co., Bristol Myers Squibb, F. Hoffmann-La Roche Ltd., and AstraZeneca are investing heavily in research and development to improve existing therapies and develop new targeted therapies. The increasing availability of companion diagnostic tests is helping identify patients eligible for these targeted therapies further expanding the market.",
  "shortSummary": "The global NSCLC treatment market is rapidly growing due to advancements in immunotherapies and targeted therapies, but challenges remain due to high treatment costs and drug resistance.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "1350730cb3c1447ab50bc326a15e69bc",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://www.researchandmarkets.com/reports/6155723/non-small-cell-lung-cancer-market-global?utm_source=GNE&utm_medium=PressRelease&utm_code=gvhppk&utm_campaign=2088272+-+Non-Small+Cell+Lung+Cancer+(NSCLC)+Market+Growth+Trends+and+Business+Opportunities+2025-2035+by+Region&utm_exec=jocamspi",
      "text": "10% Free customization\nNon-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all cases. It is a malignant tumor that begins in the cells lining the lungs and can spread to other parts of the body if left untreated. NSCLC is typically categorized into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The progression of NSCLC can be slow or rapid, and symptoms often emerge only in the later stages, including persistent cough, shortness of breath, chest pain, and weight loss. Early detection of NSCLC is challenging, as it often does not show significant symptoms until the disease has advanced. Smoking remains the primary risk factor for NSCLC, although non-smokers can also develop the disease, particularly in cases of adenocarcinoma. Environmental factors, such as exposure to second-hand smoke, radon, or asbestos, can also contribute to the development of lung cancer.This report comes with 10% free customization, enabling you to add data that meets your specific business needs.\nThe diagnosis of NSCLC typically involves imaging tests such as chest X-rays, CT scans, and PET scans, which are used to detect abnormalities in the lungs and identify the size and spread of the tumor. A biopsy, often performed through bronchoscopy or needle aspiration, is necessary to confirm the diagnosis and determine the specific subtype of NSCLC. Molecular testing is increasingly important in diagnosing NSCLC, as it helps identify specific genetic mutations, such as EGFR mutations, ALK rearrangements, and ROS1 fusions, that can inform treatment decisions. Advances in liquid biopsy technology, which detects genetic mutations in blood samples, are also making it easier to identify these biomarkers in patients who cannot undergo traditional biopsy procedures.\nThe global NSCLC treatment market is experiencing rapid growth, driven by advancements in immunotherapies, targeted therapies, and combination treatments. The introduction of immune checkpoint inhibitors, such as pembrolizumab and nivolumab, has revolutionized the treatment landscape, offering significant improvements in survival rates for patients with advanced NSCLC. These therapies work by stimulating the body's immune system to target and destroy cancer cells. Additionally, targeted therapies that focus on specific genetic mutations, including EGFR inhibitors, ALK inhibitors, and ROS1 inhibitors, are improving outcomes for patients with specific molecular alterations. These therapies are often more effective than traditional chemotherapy and tend to have fewer side effects, offering more personalized treatment options for patients.\nThe NSCLC market is also witnessing significant advancements in combination therapies, which combine different classes of drugs, such as immune checkpoint inhibitors with chemotherapy or targeted therapies, to enhance efficacy and overcome resistance mechanisms. Ongoing clinical trials are exploring the potential of combining immunotherapy with other novel treatments, such as targeted agents, to achieve better results. Furthermore, the development of novel immunotherapies, including CAR-T cell therapies and cancer vaccines, is expected to further expand treatment options and improve patient outcomes.\nDespite these advancements, the NSCLC market faces several challenges. One of the major barriers is the high cost of immunotherapies and targeted therapies, which can be prohibitively expensive, particularly in low- and middle-income countries. The cost of treatment often places a heavy financial burden on patients and healthcare systems. Additionally, not all patients respond to immunotherapies or targeted therapies, and the development of resistance remains a significant hurdle. Limited awareness of NSCLC, particularly in regions with less access to healthcare, contributes to late-stage diagnosis and delays in treatment initiation. Furthermore, the complexity of personalized treatment regimens, which require molecular testing and continuous monitoring, adds to the challenges of managing NSCLC effectively.\nKey players in the NSCLC treatment market include major pharmaceutical companies such as Merck & Co., Bristol Myers Squibb, F. Hoffmann-La Roche Ltd., and AstraZeneca. These companies are investing heavily in research and development to improve existing therapies, develop new targeted therapies, and explore novel immunotherapy options. Strategic partnerships with research institutions, healthcare providers, and patient advocacy groups are accelerating efforts to expand access to innovative treatments and improve early detection methods. Furthermore, collaborations between biotech firms and pharmaceutical giants are advancing the development of new therapies and diagnostic solutions aimed at improving survival rates and the overall quality of life for NSCLC patients.\nThe global non-small cell lung cancer (NSCLC) treatment market is experiencing significant growth, driven by advancements in immunotherapies, targeted therapies, and a rising global incidence of lung cancer. Innovations in immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have revolutionized the treatment landscape by offering improved survival rates, particularly in advanced-stage patients. Additionally, the development of targeted therapies targeting specific genetic mutations, such as EGFR, ALK, and ROS1 inhibitors, is transforming NSCLC treatment by providing more effective, personalized, and less toxic alternatives to traditional chemotherapy. The increasing availability of companion diagnostic tests is enhancing the identification of patients who are eligible for these targeted therapies, further expanding the market. Furthermore, the ongoing research into combination therapies, which combine immune checkpoint inhibitors with chemotherapy or targeted therapies, presents promising opportunities for enhancing efficacy and overcoming treatment resistance. The growing adoption of liquid biopsy techniques is also contributing to early detection and better monitoring of treatment responses, thereby driving demand for advanced therapies in the NSCLC market.\nThis product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.\nTable of Contents\nExecutive SummaryScope and DefinitionMarket/Product DefinitionInclusion and ExclusionKey Questions AnsweredAnalysis and Forecast Note4. Research Methodology\n1. Global Non-Small Cell Lung Cancer Market: Industry Analysis\n2. Global Non-Small Cell Lung Cancer Market, by Region, ($Million), 2024-2035\n3. Global Non-Small Cell Lung Cancer Market: Competitive Landscape and Company Profiles\nList of Figures\nList of Tables\nCompanies Mentioned\n- AstraZeneca\n- Bayer AG\n- Boehringer Ingelheim International GmbH\n- Bristol-Myers Squibb\n- Eli Lilly and Company\n- F. Hoffmann-La Roche Ltd.\n- GSK plc\n- Merck & Co., Inc\n- Novartis AG\n- Pfizer Inc.\n- Sanofi\n- Teva Pharmaceuticals"
    }
  ],
  "argos_summary": "The global non\u2011small cell lung cancer (NSCLC) treatment market is projected to grow rapidly through 2035, driven by advances in immunotherapies, targeted therapies, and combination regimens that improve survival and reduce side effects. Key innovations include immune checkpoint inhibitors (pembrolizumab, nivolumab), EGFR/ALK/ROS1 inhibitors, and emerging CAR\u2011T and vaccine approaches, alongside liquid biopsy and companion diagnostics that broaden patient access. However, high drug costs, resistance, and limited awareness in low\u2011 and middle\u2011income regions remain significant barriers, prompting major pharma players to pursue collaborations and R&D to expand affordable options and early detection strategies.",
  "argos_id": "E1S46520V"
}